Antengene (FRA:722) Cash Flow for Dividends: €0.00 Mil (TTM As of Dec. 2025)


FRA:722 Antengene Corp Ltd FRA:722
40 GF Score
Price €0.35
GF Value €0.16
! 5 Warning Signs
View Full Analysis

What is Antengene Cash Flow for Dividends?

Antengene FRA:722 -3.33% 40 Cash Flow for Dividends is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:722 with a GF Score™ of 40/100 and a GF Value™ of €0.16. The stock has 5 warning signs investors should review.

Antengene's cash flow for dividends for the six months ended in Dec. 2025 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Antengene Cash Flow for Dividends Related Terms

Antengene Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Antengene's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antengene Cash Flow for Dividends Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:722
40GF Score
Antengene Corp Ltd FRA:722
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antengene Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0.00 Mil mean?
Antengene (FRA:722) has a Cash Flow for Dividends of €0.00 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Antengene and its competitors.
Is Antengene's Cash Flow for Dividends too high?
Antengene's current Cash Flow for Dividends is €0.00 Mil. Overall, Antengene has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Antengene's Cash Flow for Dividends compare to VRTX and REGN?
Antengene's Cash Flow for Dividends of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Antengene and its competitors. Antengene's current Cash Flow for Dividends is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antengene stock overvalued right now?
Antengene (FRA:722) has a current Cash Flow for Dividends of €0.00 Mil. The stock's GF Value™ is €0.16, compared to a current price of €0.35 — trading 117.5% above its estimated fair value. The current Cash Flow for Dividends is €0.00 Mil. Antengene's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Antengene (FRA:722), the current Cash Flow for Dividends is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Antengene (FRA:722) Overvalued in 2026?

Based on GuruFocus' analysis, Antengene stock appears to be overvalued. The current stock price of €0.35 is trading 117.5% above its estimated GF Value™ of €0.16.

Key valuation signals for FRA:722:

  • Cash Flow for Dividends: €0.00 Mil
  • GF Value™: €0.16 vs. price of €0.35 (117.5% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the FRA:722 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Antengene Business Description

Other Exchanges 06996:Hong Kong
Address 1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically, it operates in the Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
40GF Score

Get the complete analysis for FRA:722

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.35
Price
€0.16
GF Value